Tumor Antigen Escape from CAR T-cell Therapy.
By R. Majzner, C. Mackall. Cancer Discovery, 2018
953 citations recorded by the source corpus.
Emerging data from chimeric antigen receptor (CAR) T-cell trials in B-cell malignancies demonstrate that a common mechanism of resistance to this novel class of therapeutics is the emergence of tumors with loss or downregulation of the target antigen. Antigen loss or antigen-low escape is likely to emerge as an even greater barrier to success in solid tumors, which manifest greater heterogeneity in target antigen expression. Potential approaches to overcome this challenge include engineering CAR T cells to achieve multispecificity and to respond to lower levels of target antigen and more efficient induction of natural antitumor immune responses as a result of CAR-induced inflammation. In this article, we review the evidence to date for antigen escape and downregulation and discuss approaches currently under study to overcome these obstacles.Significance: Antigen escape and downregulation have emerged as major issues impacting the durability of CAR T-cell therapy. Here, we explore their incidence and ways to overcome these obstacles in order to improve clinical outcomes. Cancer Discov; 8(10); 1219-26. ©2018 AACR.
Subfields: Biomedical Engineering, Electrical and Electronic Engineering, Oncology
View Paper: https://www.semanticscholar.org/paper/6cec9239535731b8731b0822810229ccbd6cdae2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biomedical Engineering
In Oncology
Citations in the corpus
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy (2019, result): “For example, reports from multiple trials and institutional studies have indicated that 7–25% of patients treated with CD19-targeted CAR T cells relapsed with CD19 – disease 108 .”